Clinical Trials Sponsored by Genentech, Inc.

Total 35763 results

Genentech, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Alzheimer's Disease

United States, Spain, France, Canada, Germany, United Kingdom
Genentech, Inc.

Completed

A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Head and Neck Cancer

Belgium, United States
Genentech, Inc.

Withdrawn

A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation

Kidney Transplantation
Genentech, Inc.

Completed

The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)

Healthy | Asthma
Genentech, Inc.

Completed

A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) (AMBER)

Multiple Myeloma
Genentech, Inc.

Completed

A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma (AERO)

Asthma
Genentech, Inc.

Completed

Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer

Non-Small Cell Lung Cancer, Ovarian Cancer

Spain, United States
Genentech, Inc.

Completed

A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)

Colorectal Cancer
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Cancers
Genentech, Inc.

Completed

A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease

Cystic Fibrosis
Genentech, Inc.

Withdrawn

A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

Carcinoma
Genentech, Inc.

Completed

An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO

Choroidal Neovascularization, Age-related Macular Degeneration
Genentech, Inc.

Completed

An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)

Healthy Volunteers
Genentech, Inc.

Completed

Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Genentech, Inc.

Completed

A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE) (RISE)

Diabetes Mellitus | Macular Edema
Genentech, Inc.

Withdrawn

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g

Lupus Nephritis
Genentech, Inc.

Completed

A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Metastatic Breast Cancer
Genentech, Inc.

Completed

A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model

Healthy Volunteer

United Kingdom
Genentech, Inc.

Completed

A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer

Ovarian Cancer
Genentech, Inc.

Completed

An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)

Acute Myocardial Infarction
Genentech, Inc.

Completed

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

Lymphocytic Leukemia, Chronic

United States
Genentech, Inc.

Completed

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters (TROPICS 4)

Dysfunctional Hemodialysis Catheters
Genentech, Inc.

Terminated

A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis

Cystic Fibrosis
Genentech, Inc.

Completed

A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Ovarian Cancer

Netherlands, United States
Genentech, Inc.

Terminated

A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device

Growth Hormone Deficiency

United States
Genentech, Inc.

Completed

Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors

Solid Tumor

United States
Genentech, Inc.

Completed

A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

Asthma

United States, Australia
Genentech, Inc.

Completed

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
Genentech, Inc.

Completed

A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Cancers

United States, United Kingdom, France
Genentech, Inc.

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Solid Cancers

United States
Genentech, Inc.

Completed

A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Multiple Myeloma, Neoplasms

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Solid Cancers

United States, Spain
Genentech, Inc.

Completed

Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Ovarian Cancer, Pancreatic Cancer

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors

Solid Cancers

United States
Genentech, Inc.

Completed

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

Ulcerative Colitis

Belgium, United States, Canada, Germany, Netherlands, United Kingdom
Genentech, Inc.

Completed

A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy

Geographic Atrophy

Germany, United States
Genentech, Inc.

Completed

A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

Healthy Volunteer

United States
Genentech, Inc.

Completed

The Management of Schizophrenia in Clinical Practice (MOSAIC)

Schizophrenia

United States
Genentech, Inc.

Completed

Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers

Healthy Volunteer

Canada
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

United States, France, Netherlands
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Cancers

United States
Genentech, Inc.

Approved for marketing

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Urothelial Carcinoma

United States
Genentech, Inc.

Withdrawn

Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

Renal Cell Cancer
Genentech, Inc.

Completed

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Belgium, United States, Spain, Australia, Poland
Genentech, Inc.

Completed

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

Belgium, Spain, New Zealand, United States, Czech Republic, Germany, Australia, United Kingdom, Israel, Hungary, Canada
Genentech, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Poland, United States, Colombia, Russian Federation, Mexico, Argentina
Genentech, Inc.

Completed

A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Endometrial Carcinoma

United States

3

Subscribe